DMKJ

David M. Knott Jr Portfolio holdings

AUM $189M Turnover 22.11%
1-Year Est. Return 67.72%
This Fund
S&P 500
This Quarter Est. Return
+18%
1 Year Est. Return
+67.72%
3 Year Est. Return
+169.37%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$189M
AUM Growth
+$21.1M
Cap. Flow
-$3.54M
Cap. Flow %
-1.87%
Top 10 Hldgs %
62.82%
Holding
95
New
10
Increased
16
Reduced
4
Closed
11
Avg Time Held
2.3 years
Top 10 Avg Time Held
1.4 years
Top 20 Avg Time Held
1.2 years

Top Buys

Rank Stock Value
1
CLST icon
Catalyst Bancorp
CLST
+$1.84M
2
SPRB icon
Spruce Biosciences
SPRB
+$1.12M
3
CGEM icon
Cullinan Oncology
CGEM
+$668K
4
INSM icon
Insmed
INSM
+$515K
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$512K

Top Sells

Rank Stock Value
1
CPRX icon
Catalyst Pharmaceutical
CPRX
+$2.97M
2
ACLX icon
Arcellx
ACLX
+$2.23M
3
CYTK icon
Cytokinetics
CYTK
+$1.56M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$1.55M
5
TGTX icon
TG Therapeutics
TGTX
+$948K

Sector Composition

Rank Sector Weight
1 Healthcare 52.57%
2 Financials 20.08%
3 Communication Services 17.13%
4 Miscellaneous 7.75%
5 Technology 1.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GOOG icon
1
Alphabet (Google) Class C
GOOG
$4.2T
$32.3M 17.07%
91,420
– –
2021 Q4
18 quarters
APO icon
2
Apollo Global Management
APO
$67B
$26.6M 14.07%
225,000
– –
2021 Q4
18 quarters
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.21B
$9.56M 5.05%
437,245
+15,245
+4% +$317K
2024 Q1
9 quarters
XERS icon
4
Xeris Biopharma Holdings
XERS
$1.78B
$8.4M 4.44%
1,060,000
– –
2023 Q4
10 quarters
TVTX icon
5
Travere Therapeutics
TVTX
$5.02B
$8.37M 4.42%
147,282
+6,649
+5% +$295K
2023 Q3
11 quarters
PTGX icon
6
Protagonist Therapeutics
PTGX
$8.82B
$7.72M 4.08%
63,000
– –
2023 Q3
11 quarters
BBIO icon
7
BridgeBio Pharma
BBIO
$12.7B
$6.92M 3.66%
92,850
+2,850
+3% +$200K
2025 Q2
4 quarters
IOVA icon
8
Iovance Biotherapeutics
IOVA
$6.44B
$6.66M 3.52%
1,600,000
– –
2026 Q1
1 quarter
ALKS icon
9
Alkermes
ALKS
$6.56B
$6.38M 3.37%
121,759
+1,759
+1% +$68.7K
2025 Q2
4 quarters
JPM icon
10
JPMorgan Chase
JPM
$890B
$5.92M 3.13%
18,098
-1,379
-7% -$428K
2021 Q4
18 quarters
JAAA icon
11
Janus Henderson AAA CLO ETF
JAAA
$32.1B
$4.72M 2.5%
93,528
– –
2023 Q3
11 quarters
COGT icon
12
Cogent Biosciences
COGT
$4.88B
$4.3M 2.27%
111,081
+7,081
+7% +$248K
2025 Q4
2 quarters
TGTX icon
13
TG Therapeutics
TGTX
$8.32B
$3.67M 1.94%
66,839
-23,162
-26% -$948K
2025 Q4
2 quarters
CLST icon
14
Catalyst Bancorp
CLST
$69.6M
$3.58M 1.89%
+114,000
New +$1.84M
2026 Q2
0 quarters
AGIO icon
15
Agios Pharmaceuticals
AGIO
$1.85B
$3.53M 1.86%
95,058
+2,000
+2% +$60.7K
2025 Q4
2 quarters
VRDN icon
16
Viridian Therapeutics
VRDN
$2.08B
$3.32M 1.76%
181,000
– –
2024 Q4
6 quarters
RLMD icon
17
Relmada Therapeutics
RLMD
$346M
$3.12M 1.65%
451,000
+11,700
+3% +$81.8K
2026 Q1
1 quarter
RCUS icon
18
Arcus Biosciences
RCUS
$2.87B
$2.5M 1.32%
81,241
– –
2025 Q1
5 quarters
HELP
19
Helus Pharma Inc. Common Stock
HELP
$758M
$2.45M 1.29%
370,000
+20,000
+6% +$100K
2024 Q4
6 quarters
XBI icon
20
State Street SPDR S&P Biotech ETF
XBI
$9.71B
$2.37M 1.25%
15,000
– –
2023 Q4
10 quarters
RZLT icon
21
Rezolute
RZLT
$409M
$1.92M 1.02%
370,000
– –
2025 Q3
3 quarters
AB icon
22
AllianceBernstein
AB
$3.16B
$1.69M 0.89%
48,000
– –
2021 Q4
18 quarters
MDGL icon
23
Madrigal Pharmaceuticals
MDGL
$10.6B
$1.61M 0.85%
3,000
+1,000
+50% +$512K
2025 Q2
4 quarters
ATRC icon
24
AtriCure
ATRC
$2.91B
$1.44M 0.76%
51,400
– –
2025 Q1
5 quarters
DCGO icon
25
DocGo
DCGO
$26.9M
$1.38M 0.73%
2,670,850
– –
2021 Q4
18 quarters
1
2 3 4

Similar funds

SCA
Sander Capital Advisors Seattle, Washington $189M AUM 13.06% 1-Year Est. Return
FI
FWG Investments Lexington, Kentucky $189M AUM 18.47% 1-Year Est. Return
MFS
Madrid Financial Services Manhattan Beach, California $189M AUM 30.12% 1-Year Est. Return
FRA
FFG Retirement Advisors Centennial, Colorado $189M AUM 16.39% 1-Year Est. Return
CAM
Councilmark Asset Management Knoxville, Tennessee $189M AUM 26.93% 1-Year Est. Return
BAG
Bauman Advisory Group Las Vegas, Nevada $189M AUM
SHC
SALT Holding Corp Wilmington, Delaware $189M AUM 34.63% 1-Year Est. Return
HC
Hara Capital Bellevue, Washington $190M AUM 42.56% 1-Year Est. Return

David M. Knott Jr's Q2 2026 Portfolio in Review

As of Q2 2026, David M. Knott Jr held 95 positions worth $189M, up 13% from $168M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

David M. Knott Jr's Q2 2026 filing shows 10 new, 16 increased, 4 reduced and 11 closed positions. Its largest new stake was Catalyst Bancorp: 114,000 shares worth $3.58M. The largest sale was Catalyst Pharmaceutical, an estimated $2.97M.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 54% a quarter earlier, followed by Financials and Communication Services.

  • David M. Knott Jr's largest Q2 2026 buy was Catalyst Bancorp: 114,000 shares worth $3.58M.
  • David M. Knott Jr added most to Cullinan Oncology in Q2 2026, an estimated $668K increase.
  • David M. Knott Jr's biggest Q2 2026 reduction was TG Therapeutics, cutting an estimated $948K.
  • David M. Knott Jr fully exited Catalyst Pharmaceutical in Q2 2026, selling an estimated $2.97M.
  • David M. Knott Jr's ten largest holdings make up 63% of its $189M portfolio in Q2 2026.
  • David M. Knott Jr opened 10 new positions and closed 11 in Q2 2026.
  • David M. Knott Jr's portfolio value rose 13% quarter-over-quarter to $189M.

Based on David M. Knott Jr's 13F filing for Q2 2026, filed 12 Aug 2026.